Patricia Carey

Dec 27, 2024 | onlinelibrary.wiley.com | Patricia Carey |Animesh Pardanani |Patrick Starlinger |Ayalew Tefferi

To the Editor, The management of symptomatic splenomegaly in myelofibrosis (MF) was revolutionized by the discovery of the JAK2V617F mutation and subsequent development of JAK2 inhibitors (JAKi) [1-4]. Currently, four JAKi are approved by the Food and Drug Administration (FDA) for treatment of MF: ruxolitinib, fedratinib, pacritinib, and momelotinib which alleviate symptomatic splenomegaly and constitutional symptoms. In the COMFORT I (ruxolitinib vs.